Canadian consensus conference on dementia: Two years later

Canadian Journal of Neurological Sciences

Volumn 28, Issue SUPPL. 1, 2001, Pages

  Patterson, C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; GENETIC PREDISPOSITION; HALLUCINATION; HUMAN; PRIORITY JOURNAL;

EID: 0035107158     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100001153     Document Type: Conference Paper

References (13)

1. Mild cognitive impairment. Clinical characterization and outcome
2. Mild cognitive impairment: Conceptual basis and current nosological status
3. The genetics of Alzheimer disease
4. Causes of Alzheimer's disease
5. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
6. Efficacy and safety of rivastigmine in patients with Alzheimer's Disease: International randomised controlled trial
7. Galantamine in AD. A 6-month randomized, placebo-controlled trial with a 6-month extension
8. A 5-month randomized, placebo-controlled trial of galantamine in AD
9. Benefits of donepezil on global function, behaviour, cognition, and ADLs in patients with moderate-to-severe Alzheimer's disease
10. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patient
11. A randomized trial of risperidone, placebo, and haloperidol for behavioural symptoms of dementia
12. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomized, double-blind trial
13. Antipsychotic agents in patients with dementia